SCHEMBL2632950

SCHEMBL2632950

CCC(C)n1ccc2cccc(Cl)c21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.45
SLC6A2 P23975 2/20 0.43
SLC6A4 P31645 2/20 0.43
BACE1 P56817 1/20 0.36
ADRA2A P08913 1/20 0.36
ADRA2B P18089 1/20 0.36
ADRA2C P18825 1/20 0.36
MC4R P32245 1/20 0.35
NPY5R Q15761 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
PSMB8 P28062 2/20 0.33
HTR2C P28335 1/20 0.33
PRMT5 O14744 1/20 0.33
CYP19A1 P11511 3/20 0.32
S1PR1 P21453 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2A6 P11509 1/20 0.31
KDM4E B2RXH2 1/20 0.30
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21725644 0.82 SLC6A2 (0.44) HTR2ASLC6A2SLC6A4BACE1ADRA2A
SCHEMBL27668191 0.78 SLC6A2 (0.46) HTR2ASLC6A2SLC6A4BACE1MEN1
SCHEMBL12081932 0.77 HTR2A (0.74) HTR2AMEN1KMT2AHTR2CCYP1A2
SCHEMBL22871225 0.76 HTR2A (0.42) HTR2AMEN1KMT2AHTR2CCYP19A1
SCHEMBL21725659 0.76 HTR2A (0.42) HTR2ASLC6A2SLC6A4HTR2CCYP19A1
SCHEMBL12383495 0.73 NOTUM (0.45) HTR2ASLC6A2SLC6A4MC4RNPY5R
SCHEMBL24729036 0.72 SLC6A2 (0.49) HTR2ASLC6A2SLC6A4
SCHEMBL599150 0.72 SLC6A2 (0.49) HTR2ASLC6A2SLC6A4
SCHEMBL14473516 0.72 ADRA2A (0.49) HTR2ASLC6A2SLC6A4BACE1ADRA2A
SCHEMBL30638824 0.71 HTR2A (0.46) HTR2ASLC6A2SLC6A4BACE1ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11566015-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2023-01-31 US disclosed
US-20210238164-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2021-08-05 US disclosed
US-10981894-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2021-04-20 US disclosed
US-20130035310-A1 Piperidine and Piperazine Phenyl Sulfonamides as Modulators of Ion Channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-02-07 US disclosed
US-8163720-B2 Pyrrolidinyl phenyl sulphonamides as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-04-24 US disclosed
US-20110082117-A1 PHENYL SULFONAMIDES AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11566015-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R HTR2A 21/4885SLC6A2 341/4885SLC6A4 612/4885
US-20210238164-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF MC3R, MC1R, MC2R HTR2A 21/4885SLC6A2 341/4885SLC6A4 612/4885
US-20110082117-A1 PHENYL SULFONAMIDES AS MODULATORS OF ION CHANNELS TRPV1, KCNJ2, TRPA1 HTR2A 724/4885SLC6A2 446/4885SLC6A4 252/4885
US-20130035310-A1 Piperidine and Piperazine Phenyl Sulfonamides as Modulators of Ion Channels TRPV1, TRPV5, TRPA1 HTR2A 408/4885SLC6A2 993/4885SLC6A4 520/4885
US-10981894-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R HTR2A 21/4885SLC6A2 341/4885SLC6A4 612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.